Antios Therapeutics
Signal active
Organization
Contact Information
Overview
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.
Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
About
Industries
Biotechnology, Biopharma, Therapeutics
Founded
2018
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Antios Therapeutics headquartered in United States, North America, operates in the Biotechnology, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $9.6B in funding across 48 round(s). With a team of 11-50 employees, Antios Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Antios Therapeutics, raised $75.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
20
Lead Investors
0
Total Funding Amount
$200.4M
Details
3
Antios Therapeutics has raised a total of $200.4M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | 25.0M | ||
| 2021 | Early Stage Venture | 96.0M | ||
| 2021 | Early Stage Venture | 75.0M |
Investors
Antios Therapeutics is funded by 55 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Nicole Vitullo | - | FUNDING ROUND - Nicole Vitullo | 75.0M |
| Domain Associates | - | FUNDING ROUND - Domain Associates | 75.0M |
| Antios Therapeutics | - | FUNDING ROUND - Antios Therapeutics | 75.0M |
| Antios Therapeutics | - | FUNDING ROUND - Antios Therapeutics | 75.0M |
Recent Activity
There is no recent news or activity for this profile.